Literature DB >> 21458391

Longitudinal association between medication adherence and lung health in people with cystic fibrosis.

Michelle N Eakin1, Andrew Bilderback, Michael P Boyle, Peter J Mogayzel, Kristin A Riekert.   

Abstract

BACKGROUND: This study examined the relationship of medication adherence to frequency of pulmonary exacerbation and rate of decline in FEV(1)% predicted (FEV(1)).
METHODS: 95 CF patients aged 6 years or older and prescribed a pulmonary medication, were enrolled in a longitudinal retrospective review of medication adherence and health outcomes (the occurrence and frequency of intravenous (IV) antibiotic treatments and FEV(1)) over 12-months. Pharmacy refill records were used to calculate a medication possession ratio (MPR).
RESULTS: Composite MPR predicted the occurrence of at least one pulmonary exacerbation requiring a course of IV antibiotics (IRR=2.34, p=0.05), but not the frequency of exacerbations, after controlling for gender, baseline FEV(1,) and regimen complexity. Composite MPR predicted baseline FEV(1) (estimate=29.81, p=.007), but not decline in FEV(1).
CONCLUSIONS: These results demonstrate a significant relation between medication adherence and IV antibiotics in CF patients, highlighting the importance of addressing adherence during clinic visits to improve health outcomes.
Copyright © 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21458391      PMCID: PMC3114200          DOI: 10.1016/j.jcf.2011.03.005

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  35 in total

1.  Composite outcomes in randomized trials: greater precision but with greater uncertainty?

Authors:  Nick Freemantle; Melanie Calvert; John Wood; Joanne Eastaugh; Carl Griffin
Journal:  JAMA       Date:  2003-05-21       Impact factor: 56.272

2.  Spirometric reference values from a sample of the general U.S. population.

Authors:  J L Hankinson; J R Odencrantz; K B Fedan
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

Review 3.  The assessment of refill compliance using pharmacy records: methods, validity, and applications.

Authors:  J F Steiner; A V Prochazka
Journal:  J Clin Epidemiol       Date:  1997-01       Impact factor: 6.437

4.  Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis.

Authors:  Lisa Saiman; Nicole Mayer-Hamblett; Preston Campbell; Bruce C Marshall
Journal:  Am J Respir Crit Care Med       Date:  2005-07-22       Impact factor: 21.405

5.  Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group.

Authors:  K McCoy; S Hamilton; C Johnson
Journal:  Chest       Date:  1996-10       Impact factor: 9.410

6.  Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy.

Authors:  P W Choo; C S Rand; T S Inui; M L Lee; E Cain; M Cordeiro-Breault; C Canning; R Platt
Journal:  Med Care       Date:  1999-09       Impact factor: 2.983

7.  Identifying treatments that halt progression of pulmonary disease in cystic fibrosis.

Authors:  P B Davis; P J Byard; M W Konstan
Journal:  Pediatr Res       Date:  1997-02       Impact factor: 3.756

8.  Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.

Authors:  B W Ramsey; M S Pepe; J M Quan; K L Otto; A B Montgomery; J Williams-Warren; M Vasiljev-K; D Borowitz; C M Bowman; B C Marshall; S Marshall; A L Smith
Journal:  N Engl J Med       Date:  1999-01-07       Impact factor: 91.245

9.  Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.

Authors:  H J Fuchs; D S Borowitz; D H Christiansen; E M Morris; M L Nash; B W Ramsey; B J Rosenstein; A L Smith; M E Wohl
Journal:  N Engl J Med       Date:  1994-09-08       Impact factor: 91.245

10.  Compliance among adults with cystic fibrosis.

Authors:  S L Fong; R E Dales; M G Tierney
Journal:  DICP       Date:  1990 Jul-Aug
View more
  67 in total

1.  Preferences and Stated Adherence for Antibiotic Treatment of Cystic Fibrosis Pseudomonas Infections.

Authors:  Ateesha Farah Mohamed; F Reed Johnson; Maria-Magdalena Balp; Frederico Calado
Journal:  Patient       Date:  2016-02       Impact factor: 3.883

2.  Precision Medicine In Action: The Impact Of Ivacaftor On Cystic Fibrosis-Related Hospitalizations.

Authors:  Lisa B Feng; Scott D Grosse; Ridgely Fisk Green; Aliza K Fink; Gregory S Sawicki
Journal:  Health Aff (Millwood)       Date:  2018-05       Impact factor: 6.301

3.  Objective Versus Self-Reported Adherence to Airway Clearance Therapy in Cystic Fibrosis.

Authors:  Gabriela R Oates; Irena Stepanikova; Steven M Rowe; Stephanie Gamble; Hector H Gutierrez; William T Harris
Journal:  Respir Care       Date:  2018-12-11       Impact factor: 2.258

4.  Adherence to airway clearance therapy in pediatric cystic fibrosis: Socioeconomic factors and respiratory outcomes.

Authors:  Gabriela R Oates; Irena Stepanikova; Stephanie Gamble; Hector H Gutierrez; William T Harris
Journal:  Pediatr Pulmonol       Date:  2015-10-05

5.  Motivating adherence among adolescents with cystic fibrosis: youth and parent perspectives.

Authors:  Gregory S Sawicki; Karen S Heller; Nathan Demars; Walter M Robinson
Journal:  Pediatr Pulmonol       Date:  2014-03-10

6.  Association of Medication Adherence and Clinical Outcomes in Sarcoidosis.

Authors:  Michelle Sharp; Taylor Brown; Edward S Chen; Cynthia S Rand; David R Moller; Michelle N Eakin
Journal:  Chest       Date:  2020-02-04       Impact factor: 9.410

7.  Medication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis.

Authors:  Marisa E Hilliard; Michelle N Eakin; Belinda Borrelli; Angela Green; Kristin A Riekert
Journal:  Health Psychol       Date:  2014-08-11       Impact factor: 4.267

8.  Pharmacists' perspectives on monitoring adherence to treatment in Cystic Fibrosis.

Authors:  Karen Mooney; Cristín Ryan; Damian G Downey
Journal:  Int J Clin Pharm       Date:  2015-12-29

9.  Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes.

Authors:  Gregory S Sawicki; Clement L Ren; Michael W Konstan; Stefanie J Millar; David J Pasta; Alexandra L Quittner
Journal:  J Cyst Fibros       Date:  2013-01-24       Impact factor: 5.482

Review 10.  Tackling the increasing complexity of CF care.

Authors:  Gregory S Sawicki; Christopher H Goss
Journal:  Pediatr Pulmonol       Date:  2015-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.